1772 related articles for article (PubMed ID: 27782834)
1. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
[TBL] [Abstract][Full Text] [Related]
2. Poly Lactic-co-Glycolic Acid Nanoparticles Containing Human Gastric Tumor Lysates as Antigen Delivery Vehicles for Dendritic Cell-Based Antitumor Immunotherapy.
Kohnepoushi C; Nejati V; Delirezh N; Biparva P
Immunol Invest; 2019 Nov; 48(8):794-808. PubMed ID: 31094258
[TBL] [Abstract][Full Text] [Related]
3. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells.
Heo MB; Cho MY; Lim YT
Acta Biomater; 2014 May; 10(5):2169-76. PubMed ID: 24394635
[TBL] [Abstract][Full Text] [Related]
4. pH-Responsive Poly(D,L-lactic-co-glycolic acid) Nanoparticles with Rapid Antigen Release Behavior Promote Immune Response.
Liu Q; Chen X; Jia J; Zhang W; Yang T; Wang L; Ma G
ACS Nano; 2015 May; 9(5):4925-38. PubMed ID: 25898266
[TBL] [Abstract][Full Text] [Related]
5. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses.
Ma W; Chen M; Kaushal S; McElroy M; Zhang Y; Ozkan C; Bouvet M; Kruse C; Grotjahn D; Ichim T; Minev B
Int J Nanomedicine; 2012; 7():1475-87. PubMed ID: 22619507
[TBL] [Abstract][Full Text] [Related]
6. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.
Hamdy S; Haddadi A; Hung RW; Lavasanifar A
Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733
[TBL] [Abstract][Full Text] [Related]
7. Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine.
Jahan ST; Sadat SM; Haddadi A
Int J Nanomedicine; 2018; 13():367-386. PubMed ID: 29391795
[TBL] [Abstract][Full Text] [Related]
8. Development of a poly(d,l-lactic-co-glycolic acid) nanoparticle formulation of STAT3 inhibitor JSI-124: implication for cancer immunotherapy.
Molavi O; Mahmud A; Hamdy S; Hung RW; Lai R; Samuel J; Lavasanifar A
Mol Pharm; 2010 Apr; 7(2):364-74. PubMed ID: 20030320
[TBL] [Abstract][Full Text] [Related]
9. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy.
Han HD; Byeon Y; Kang TH; Jung ID; Lee JW; Shin BC; Lee YJ; Sood AK; Park YM
Int J Nanomedicine; 2016; 11():5729-5742. PubMed ID: 27843314
[TBL] [Abstract][Full Text] [Related]
10. Enhanced stimulation of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen.
Hanlon DJ; Aldo PB; Devine L; Alvero AB; Engberg AK; Edelson R; Mor G
Am J Reprod Immunol; 2011 Jun; 65(6):597-609. PubMed ID: 21241402
[TBL] [Abstract][Full Text] [Related]
11. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells.
Elamanchili P; Lutsiak CM; Hamdy S; Diwan M; Samuel J
J Immunother; 2007; 30(4):378-95. PubMed ID: 17457213
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses.
Diwan M; Elamanchili P; Lane H; Gainer A; Samuel J
J Drug Target; 2003; 11(8-10):495-507. PubMed ID: 15203918
[TBL] [Abstract][Full Text] [Related]
13. Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response.
Song C; Noh YW; Lim YT
Int J Nanomedicine; 2016; 11():3753-64. PubMed ID: 27540289
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
[TBL] [Abstract][Full Text] [Related]
15. Functional characterization of biodegradable nanoparticles as antigen delivery system.
Petrizzo A; Conte C; Tagliamonte M; Napolitano M; Bifulco K; Carriero V; De Stradis A; Tornesello ML; Buonaguro FM; Quaglia F; Buonaguro L
J Exp Clin Cancer Res; 2015 Oct; 34():114. PubMed ID: 26444005
[TBL] [Abstract][Full Text] [Related]
16. Rationalizing the use of functionalized poly-lactic-co-glycolic acid nanoparticles for dendritic cell-based targeted anticancer therapy.
Kokate RA; Chaudhary P; Sun X; Thamake SI; Maji S; Chib R; Vishwanatha JK; Jones HP
Nanomedicine (Lond); 2016; 11(5):479-94. PubMed ID: 26892440
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of anti-tumor effect of particulate vaccine delivery system by 'bacteriomimetic' CpG functionalization of poly-lactic-co-glycolic acid nanoparticles.
Kokate RA; Thamake SI; Chaudhary P; Mott B; Raut S; Vishwanatha JK; Jones HP
Nanomedicine (Lond); 2015; 10(6):915-29. PubMed ID: 25867857
[TBL] [Abstract][Full Text] [Related]
18. Optimization of stability, encapsulation, release, and cross-priming of tumor antigen-containing PLGA nanoparticles.
Prasad S; Cody V; Saucier-Sawyer JK; Fadel TR; Edelson RL; Birchall MA; Hanlon DJ
Pharm Res; 2012 Sep; 29(9):2565-77. PubMed ID: 22798259
[TBL] [Abstract][Full Text] [Related]
19. Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen.
Saluja SS; Hanlon DJ; Sharp FA; Hong E; Khalil D; Robinson E; Tigelaar R; Fahmy TM; Edelson RL
Int J Nanomedicine; 2014; 9():5231-46. PubMed ID: 25419128
[TBL] [Abstract][Full Text] [Related]
20. Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy.
Prasad S; Cody V; Saucier-Sawyer JK; Saltzman WM; Sasaki CT; Edelson RL; Birchall MA; Hanlon DJ
Nanomedicine; 2011 Feb; 7(1):1-10. PubMed ID: 20692374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
